The Patent Finder
US

Immunotherapy of B-Cell Malignancies Using ANTI-CD22 Antibodies

US 7,910,103 Term ended
OverviewFamilyAssignmentsSources & methods

Term ended Oct 21, 2020 · Medium confidence

Why Medium: A parent in the chain could not be resolved.

USPTO later recorded it as expired for non-payment on Apr 24, 2023.

Filed Oct 1, 2001 as application 09/965,796 · Granted Mar 22, 2011
Base term plus 954 days of patent term adjustment (USPTO delay)
Today
20 years from filing
Term ended Oct 21, 2020
1998 2026
Clock starts
Mar 12, 1998
Term ended
Oct 21, 2020
Granted
Mar 22, 2011
base term patent term adjustment after the term ends fee events Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
954
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
331
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term runs 954 days past its 20-year base term on prosecution delay. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Mar 12, 1998, when application 09/038,955, the earliest non-provisional in its chain, was filed (this one was filed Oct 1, 2001); a parent in its chain could not be resolved (the next row)Mar 12, 2018High confidence
Continuity chainA parent in the chain could not be resolveddated from this application's own claimMedium confidence
Patent term adjustment+954 days, USPTO patent term adjustment recordOct 21, 2020High confidence
Terminal disclaimer capNone on recordno cap appliedHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events2 of 2 maintenance fees paidterm endedHigh confidence
USPTO status recordRecorded as expired for non-payment on Apr 24, 2023, after the term endedno changeHigh confidence
Computed term endThe steps above, in orderOct 21, 2020Medium confidence

This family

Application 09/921,290Abandoned
not computed
not computed
US 7,910,103this patent
Oct 2020
Oct 2020
Application 10/350,096Abandoned
not computed
not computed
US 7,312,318Term ended
Jun 2024
Jun 2024
US 7,238,785Lapsed on the fee record
Jul 2019
Jul 2019
US 7,282,567Lapsed on the fee record
Oct 2019
Oct 2019
US 7,829,064Term ended
May 2021
May 2021
US 7,585,491Term ended
Jul 2024
Jul 2024
8 of 331 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jan 15, 2020
Reel 51522, frame 909
Goldenberg, David M.Immunomedics, Inc.Assignment of Assignor's Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited